KalVista Pharmaceuticals has entered into an exclusive agreement with Pendopharm, a division of Pharmascience, to oversee the regulatory approval and commercialisation of sebetralstat in Canada.
The financial terms related to this agreement have not been disclosed.
Sebetralstat is currently under investigation as an oral, on-demand treatment for hereditary angioedema (HAE).
KalVista Pharmaceuticals CEO Ben Palleiko said: “We look forward to collaborating with Pendopharm, whose deep knowledge of the Canadian market and proven track record make them a strong partner as we work to bring sebetralstat to people living with HAE.
“This partnership supports our broader goal of making sebetralstat available globally, as the first and only oral on-demand treatment that has the potential to transform HAE care.”
KalVista Pharmaceuticals specialises in developing oral therapies aimed at rare diseases with unmet medical needs.
Sebetralstat, its leading product candidate, is undergoing review by the US Food and Drug Administration (FDA) and has applications submitted to both the European Medicines Agency and other international regulatory bodies.
It functions as an oral plasma kallikrein inhibitor, specifically targeting the kallikrein-kinin system to inhibit plasma kallikrein activity responsible for triggering HAE attacks.
Sebetralstat aims to offer a non-injection alternative for individuals aged 12 and above and is being examined for use in children between two and 11 years old. Present treatments require injection or infusion, often resulting in delayed administration due to their complexity.
Pendopharm operates as speciality pharmaceutical company that partners across various therapeutic sectors, including rare diseases, to introduce innovative treatments to the Canadian market. Its collaboration with KalVista Pharmaceuticals seeks to establish sebetralstat as the first oral on-demand HAE treatment in Canada.
